CENTOCOR REOPRO CAPTURE STUDY DATA RELEASE HELPS STOCK "MARCH" UP 7 POINTS
Centocor, bolstered by the announcement of the preliminary results of the CAPTURE trial of ReoPro for adjunctive use in PTCA, marched upward 7 points to a new 1996 high of 36-1/8 at the end of March. The gain was the largest recorded for the F-D-C Index of 77 O-T-C stocks in March
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.